Imperial College Partnership Launches Programme to Combat Antimicrobial Resistance

New initiative by Fleming Initiative and LifeArc aims to strengthen antimicrobial stewardship and public engagement in tackling AMR.

Generic image of abstract medical research with glowing microscopic organisms and data visualizations.
AI

Generic image of abstract medical research with glowing microscopic organisms and data visualizations.

The Fleming Initiative and LifeArc have launched a new programme to strengthen antimicrobial stewardship (AMS), coinciding with World AMR Awareness Week.

The Fleming Initiative, a collaboration between Imperial College London and Imperial College Healthcare NHS Trust, alongside the medical research organisation LifeArc, has announced its first joint programme. This initiative is dedicated to enhancing antimicrobial stewardship (AMS), which ensures antimicrobial medicines like antibiotics and antifungals are used effectively and appropriately to treat infections.
Launched on the first day of World AMR Awareness Week, the programme highlights the escalating global threat of antimicrobial resistance (AMR). AMR is currently responsible for approximately 1.3 million deaths worldwide annually, occurring when microbes evolve resistance to treatments.
The partnership aims to foster a more proactive, evidence-based approach to AMS, building on the success of Imperial College Healthcare's existing stewardship programme, which was the first in the UK to achieve Global Antimicrobial Stewardship Accreditation and be recognised as a centre of excellence. The long-term goal is to integrate advances in diagnostics, artificial intelligence (AI), and health data into clinical decision-making for more effective antimicrobial use.
Recognising that technological progress alone is insufficient, the partnership will also focus on the human and systemic elements required for new approaches to succeed. This includes strengthening public engagement, disseminating evidence to policymakers, and fostering connections across research, healthcare, and communities, with a specific emphasis on African health systems.
The initial phase of work will bolster the Fleming Initiative’s public engagement efforts. This involves supporting its Public Advisory Group to ensure public perspectives shape the initiative's direction and developing resources for involving the public in AMR research. The programme will also investigate public understanding of AMR, attitudes towards diagnostic use in combating drug-resistant infections, and share patient stories to illustrate the real-world impact of AMR.
Research activities will explore evidence generation, translation, and application for AMS in diverse healthcare settings. Key areas include using data analytics and AI to map AMS policies globally for comparative learning, and applying behavioural science to antimicrobial prescribing and adapting successful interventions across different systems.
“

"AMS is an area where we need stronger evidence and more effective ways to translate insights into practice. This is exactly where our integrated, convergent approach can make a difference."

Professor Alison Holmes · Director of the Fleming Initiative
“

"AMR is a complex global challenge that cannot be solved by scientific innovation alone. Progress will depend on combining innovation with a deeper understanding of behaviour, health systems and people’s experiences."

Dr Toby Leslie · Director Global Health - Infection at LifeArc
“

"We’re really proud to be recognised as a global leader in antimicrobial stewardship, supporting the safe and effective use of antimicrobials across all our hospitals."

Professor Mark Gilchrist · Consultant Pharmacist Infectious Disease at Imperial College Healthcare NHS Trust
Based on information from the official source: Imperial College Healthcare NHS Trust (18/11/2026)